This move is archived. Current quotes and coverage live on the stock page.
Get HBP alerts:
Helix BioPharma Corp. faced a significant drop in stock price, closing down 4.51% in the latest trading session.
On the TSX, Helix BioPharma Corp. (HBP.TO) experienced a notable decline, closing at CA$1.27, down 4.51% from the previous day. This drop raises concerns among investors about the company's market performance and future prospects.
Advertisement
Helix BioPharma Corp.
HBP.TO
HBP.TO
Helix BioPharma Corp.
WealthAwesomeMarket cap
$156.58M
52W high
$5.40
52W low
$1.10
1W change
-2.63%
Beta
-0.35
Analyst Price Targets
Based on analyst covering HBP
Wall Street analysts forecast HBP stock price to rise 35.1% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$2.50
+35.1% Upside
Current Price
C$1.85
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HBP's historical volatility
30-Day Vol
67.2%
Annualized
90-Day Vol
65.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.21
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.96 | C$1.56 – C$2.48 |
| 60 trading days | C$2.08 | C$1.50 – C$2.89 |
| 90 trading days | C$2.21 | C$1.48 – C$3.30 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should closely monitor Helix BioPharma's financial health and market positioning, especially given the lack of recent positive news to bolster confidence.
Helix BioPharma Corp. down 4.51% in one day
The company's market cap now stands at approximately CA$107.7 million, reflecting investor sentiment and market challenges.
Bull case
Despite today's decline, Helix BioPharma has potential upside. The company is making progress with its product pipeline and is strategically moving toward attracting institutional investment, which could enhance its market position.
Bear case
The stock's drop raises concerns among investors, particularly due to the lack of recent positive news. With a market cap that suggests vulnerability, there’s a sense of caution surrounding the company’s future prospects.
Market Reaction
Advertisement
The sharp decline in Helix BioPharma's stock price can be attributed to a lack of significant news or developments that could instill confidence in investors. With a market cap of CA$107.7 million, the stock's performance reflects broader market sentiments and investor caution.
Investor Sentiment
The absence of recent positive announcements or financial results may have contributed to today's sell-off. Investors are advised to stay informed about the company's upcoming financial reports and strategic plans as they could influence future stock performance. For more insights, check the latest updates on Helix BioPharma Corp..
Looking Ahead
As Helix BioPharma navigates through this downturn, investors should keep an eye on potential catalysts that could reverse the trend. The company's ongoing efforts towards institutional investment and potential NASDAQ uplisting could play a pivotal role in shaping its future trajectory. For detailed analysis, visit our page on HBP.TO.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
